Loading…
Reported covered position: See prior filing
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Provide strategic counsel and advocate on issues related to H.R.1394/S.184 - Codifying Useful Regulatory Definitions (CURD) Act.
Provide strategic counsel and advocate on issues related to H.R.1394/S.184 - Codifying Useful Regulatory Definitions (CURD) Act.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
STRYKER CORPORATION via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide guidance and advocacy with regard to regulations and legislation that could impact the medical device industry generally, and Stryker Corporation specifically.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
RECESS via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Source: Senate LDA
| AMGEN, INC. |
| 33 |
| 2018–2026 |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 33 | 2018–2026 |
| BAYER CORPORATION | 31 | 2019–2026 |
| PFIZER, INC. | 31 | 2019–2026 |
| LOCKTON MANAGEMENT, LLC | 30 | 2018–2025 |
| MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) | 30 | 2020–2026 |
| PTC THERAPEUTICS | 29 | 2019–2026 |
| PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION | 26 | 2020–2026 |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 26 | 2020–2026 |
| RECESS | 26 | 2020–2026 |
| STRYKER CORPORATION | 25 | 2020–2026 |
| ALLIANCE FOR REGENERATIVE MEDICINE | 22 | 2022–2026 |
| ABIOMED INC | 21 | 2020–2025 |
| HORIZON PHARMA | 21 | 2019–2023 |
| ALKERMES, INC. | 20 | 2018–2026 |
| BAUDAX BIO, INC. (FORMERLY KNOWN AS RECRO PHARMA, INC.) | 18 | 2019–2022 |
| MLK COMMUNITY HEALTHCARE | 18 | 2021–2024 |
| NATIONAL RESILIENCE, INC. | 18 | 2020–2024 |
| THE ASSISTANCE FUND | 18 | 2021–2024 |
| FINDHELP | 17 | 2022–2026 |
| NOVARTIS | 17 | 2023–2026 |
| BIOMARIN PHARMACEUTICAL INC. | 16 | 2023–2026 |
| EPIGENOMICS INC. | 16 | 2019–2022 |
| Zogenix, Inc. | 16 | 2018–2022 |
| IMPOSSIBLE FOODS INC. | 15 | 2019–2022 |
| SENIOR CARE PHARMACY COALITION | 15 | 2020–2023 |
| SIEMENS HEALTHINEERS | 15 | 2019–2023 |
| ACADEMY OF NUTRITION & DIETETICS | 14 | 2024–2026 |
| BLUEBIRD BIO | 14 | 2019–2022 |
| CHARLES RIVER LABORATORIES | 14 | 2022–2025 |
| A PLACE FOR MOM, INC. | 13 | 2024–2026 |
| ADVANCING MENTAL HEALTH FOR MILITARY FAMILIES, LLC | 12 | 2023–2025 |
| ADVOCATE HEALTH | 12 | 2024–2026 |
| AMARIN PHARM INC. | 12 | 2019–2021 |
| NEKTAR THERAPEUTICS | 12 | 2019–2022 |
| TARGET ALS FOUNDATION INC. | 12 | 2022–2024 |
| BREAKTHROUGH T1D (F/K/A JDRF) | 11 | 2024–2026 |
| DISPOSERX, INC. | 11 | 2019–2021 |
| GRADY HEALTH SYSTEM | 11 | 2024–2026 |
| METLIFE GROUP, INC. (FKA METLIFE SERVICES AND SOLUTIONS, LLC) | 11 | 2021–2023 |
| NYU LANGONE HEALTH | 11 | 2024–2026 |
| PROLACTA BIOSCIENCE, INC. | 11 | 2024–2026 |
| ASSOCIATION FOR RESPONSIBLE HEALTHCARE INVESTMENT | 10 | 2025–2026 |
| MATRIX MEDICAL NETWORK | 10 | 2020–2022 |
| STAMFORD HEALTH | 10 | 2025–2026 |
| THE CHILDREN'S HOSPITAL OF PHILADELPHIA | 10 | 2025–2026 |
| UROGEN PHARMA, INC. | 10 | 2022–2024 |
| ASSOCIATION OF DENTAL SUPPORT ORGANIZATIONS | 9 | 2020–2022 |
| CARDINAL HEALTH | 9 | 2024–2026 |
| LYNDRA THERAPEUTICS | 9 | 2020–2022 |
| SAS INSTITUTE, INC. | 9 | 2021–2023 |
| Vaxcyte, Inc. | 9 | 2024–2026 |
| EVERYONE MEDICINES | 8 | 2024–2025 |
| OAK STREET HEALTH D/B/A CVS HEALTH | 8 | 2021–2022 |
| REGENTS OF THE UNIVERSITY OF MICHIGAN | 8 | 2025–2026 |
| THE PROCTER & GAMBLE COMPANY | 8 | 2025–2026 |
| UNILEVER | 8 | 2025–2026 |
| BIOMERIEUX, INC. | 7 | 2024–2025 |
| FLEXION THERAPEUTICS, INC. | 7 | 2018–2019 |
| MERCK & CO., INC. | 7 | 2018–2020 |
| TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 7 | 2025–2026 |
| AMERICAN BEVERAGE ASSOCIATION | 6 | 2021–2022 |
| Alnylam Pharmaceuticals, Inc. | 6 | 2018–2019 |
| CELGENE CORPORATION | 6 | 2018–2019 |
| HEARTLAND FOOD PRODUCTS GROUP | 6 | 2025–2026 |
| Karyopharm Therapeutics Inc. | 6 | 2018–2019 |
| SCP-HEALTH | 6 | 2021–2022 |
| WK KELLOGG CO (FKA KELLOGG COMPANY) | 6 | 2025–2026 |
| ACCUMULUS SYNERGY, INC. | 5 | 2025 |
| Altimmune, Inc. | 5 | 2020–2021 |
| ELI LILLY & CO INC | 5 | 2018–2019 |
| FAIRMOUNT FUNDS MANAGEMENT LLC | 5 | 2025–2026 |
| REAL TIME MEDICAL SYSTEMS | 5 | 2025–2026 |
| TRIO HEALTH REGULATORY ADVISORY GROUP, LLC | 5 | 2021 |
| ANCESTRY | 4 | 2019–2020 |
| CATALYST PHARMACEUTICALS | 4 | 2022 |
| EIGER BIOPHARMACEUTICALS, INC. | 4 | 2020–2021 |
| FEDERATION OF AMERICAN HOSPITALS | 4 | 2026 |
| REGENERON PHARMACEUTICALS, INC. | 4 | 2025–2026 |
| VIAL | 4 | 2025 |
| CARLSMED, INC. | 3 | 2024 |
| GLOBAL KRATOM COALITION | 3 | 2025 |
| ORCA BIO | 3 | 2026 |
| UNDIAGNOSED DISEASE NETWORK FOUNDATION | 3 | 2024 |
| MEDICOM GROUP | 2 | 2020 |
| NASSAU HEALTH SYSTEM CORP. | 2 | 2025 |
| NJOY, LLC | 2 | 2019 |
| NUVATION BIO INC. | 2 | 2026 |
| SANOFI US SERVICES INC | 2 | 2018 |
| SARGENTO FOODS INC. | 2 | 2026 |
| SOBI NORTH AMERICA | 2 | 2019 |
| CAPTOR CAPITAL CORP. | 1 | 2022 |
| FRESENIUS MEDICAL CARE | 1 | 2026 |
| PHI HEALTH, LLC, D/B/A PHI AIR MEDICAL | 1 | 2026 |
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies, EPIC Act; Most Favored Nation (MFN) policy, drug pricing policies
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies, EPIC Act; Most Favored Nation (MFN) policy, drug pricing policies
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies, EPIC Act; Most Favored Nation (MFN) policy, drug pricing policies
Provide strategic counsel and advocate on issues related to H.R.1394/S.184 - Codifying Useful Regulatory Definitions (CURD) Act.
Provide strategic counsel and advocate on issues related to H.R.1394/S.184 - Codifying Useful Regulatory Definitions (CURD) Act.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, and biopharma innovation policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies, EPIC Act; Most Favored Nation (MFN) policy, drug pricing policies
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies, EPIC Act; Most Favored Nation (MFN) policy, drug pricing policies
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, and biopharma innovation policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, biopharma innovation policies and Rare Pediatric Disease Priority Review Voucher program policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, biopharma innovation policies and Rare Pediatric Disease Priority Review Voucher program policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Long-Term Care Pharmacy Definition Act of 2021
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry; S.1574 / H.R.5632 - Long-Term Care Pharmacy Definition Act of 2021.
Long-Term Care Pharmacy Definition Act of 2021
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry; S.1574 / H.R.5632- Long-Term Care Pharmacy Definition Act of 2021.
Long-Term Care Pharmacy Definition Act of 2021
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry; S.1574 / H.R.5632- Long-Term Care Pharmacy Definition Act of 2021.
Long-Term Care Pharmacy Definition Act of 2021
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry; S.1574 / H.R.5632 - Long-Term Care Pharmacy Definition Act of 2021.
Long-Term Care Pharmacy Definition Act of 2021
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry; S.1574 / H.R.5632 - Long-Term Care Pharmacy Definition Act of 2021.
Long-Term Care Pharmacy Definition Act of 2021
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry; S.1574 / H.R.5632- Long-Term Care Pharmacy Definition Act of 2021.
Long-Term Care Pharmacy Definition Act of 2021
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry; S.1574 / H.R.5632- Long-Term Care Pharmacy Definition Act of 2021.
Long-Term Care Pharmacy Definition Act of 2021
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry; S.1574 / H.R.5632 - Long-Term Care Pharmacy Definition Act of 2021.
Long-Term Care Pharmacy Definition Act of 2021
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry; S.1574 / H.R.5632- Long-Term Care Pharmacy Definition Act of 2021.
Long-Term Care Pharmacy Definition Act of 2021
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry; S.1574 / H.R.5632- Long-Term Care Pharmacy Definition Act of 2021.
Long-Term Care Pharmacy Definition Act of 2021
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry, Congressional consideration of COVID relief packages; CARES Act Provider Relief Fund; S.1574 - Long-Term Care Pharmacy Definition Act of 2021
Long-Term Care Pharmacy Definition Act of 2021
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry, Congressional consideration of COVID relief packages; CARES Act Provider Relief Fund; S.1574 - Long-Term Care Pharmacy Definition Act of 2021
To require the Treasury to take a more prominent role in coordinating AML/CFT policy and examinations across the Government, and for other purposes.
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry, including S413, HR1316, HR1038; Congressional consideration of COVID relief packages
To require the Treasury to take a more prominent role in coordinating AML/CFT policy and examinations across the Government, and for other purposes.
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry, S413, HR1316, HR1038; Congressional consideration of COVID relief packages; CARES Act Provider Relief Fund
To require the Treasury to take a more prominent role in coordinating AML/CFT policy and examinations across the Government, and for other purposes.
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry, S413, HR1316, HR1038; Congressional consideration of COVID relief packages; CARES Act Provider Relief Fund
Federal Labor-Management Partnership Act of 2019
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry, S413, HR1316, HR1038; Congressional consideration of COVID relief packages; CARES Act Provider Relief Fund
Federal Labor-Management Partnership Act of 2019
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry, S413, HR1316, HR1038; Congressional consideration of COVID relief packages; CARES Act Provider Relief Fund
Federal Labor-Management Partnership Act of 2019
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry, including S413, HR1316, HR1038; Congressional consideration of COVID relief packages
Behavioral Health Crisis Response Improvements Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry, S413, HR1316, HR1038; Congressional consideration of COVID relief packages; CARES Act Provider Relief Fund
Behavioral Health Crisis Response Improvements Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry, S413, HR1316, HR1038; Congressional consideration of COVID relief packages; CARES Act Provider Relief Fund
Behavioral Health Crisis Response Improvements Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry, including S413, HR1316, HR1038; Congressional consideration of COVID relief packages
Provide strategic counsel and guidance regarding regulatory policy issues pertaining to CBD in food and beverage.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
BREAKTHROUGH T1D (F/K/A JDRF) via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to Type 1 Diabetes policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GRADY HEALTH SYSTEM via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and policy advocacy related to federal payment and policy issues and government funding impacting hospitals generally and Grady Health System specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, U.S. Postal Service (USPS)
VAXCYTE, INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to vaccine development
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NYU LANGONE HEALTH via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and policy analysis related to federal payment and policy issues and government funding impacting hospitals generally and NYU Langone Health specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
ACADEMY OF NUTRITION AND DIETETICS via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to health care coverage for Medical Nutritional Therapy and Intensive behavior health and other priorities for the Academy of Nutrition and Dietetics
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PROLACTA BIOSCIENCE, INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to regulation of, access to, and reimbursement for human-milk based exempt formulas
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and policy analysis related to federal payment and policy issues and government funding impacting hospitals and health plans generally and Mass General Brigham specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE
PTC THERAPEUTICS via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide guidance and advocacy with regard to regulations and legislation that could impact the pharmaceutical industry generally, and PTC specifically.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
A PLACE FOR MOM, INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic guidance and advocacy regarding the Senior Living Referral sector.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BAYER CORPORATION via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide lobbying support on key issues and providing intelligence and policy tracking for relevant federal policy developments that could impact the pharmaceutical and medical device industry generally, and Bayer specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
AMERICAN SOCIETY OF GENE AND CELL THERAPY via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Strategic advice and counsel on issues impacting gene and cell therapy development and access
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
WALGREEN CO. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide policy analysis, strategic advice and direct advocacy support to Walgreens related to public policy priorities for the retail pharmacy industry
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, White House Office
EDWARDS LIFESCIENCES LLC via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide analysis and strategic advocacy support services to Edwards Lifesciences public policy priorities, including FDA regulatory and CMS coverage and reimbursement issue
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Advise and advocate on client's behalf regarding ongoing public policy concerns impacting the innovative biotechnology industry in Congress and throughout the Administration
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
CARDINAL HEALTH via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to health, tax and trade policy
Provide strategic counsel and advocate on issues related to health, tax and trade policy
Provide strategic counsel and advocate on issues related to health, tax and trade policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
ADVOCATE HEALTH via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on health care policy, including matters impacting the hospital industry and federal appropriations
Provide strategic counsel and advocate on health care policy, including matters impacting the hospital industry and federal appropriations
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NEUROCRINE BIOSCIENCES, INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biopharmaceutical industry generally such as drug pricing and telehealth policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Providing advice, counsel, and services to support the Pharma & Biopharma Outsourcing Association's public policy priorities
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide guidance and strategic advice regarding regulation and coverage of medical devices, including diagnostic tests, in addition to supply chain matters
Filing targets: Bureau of Industry and Security (BIS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Intl Trade Administration (ITA), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
BIOMARIN PHARMACEUTICAL INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocacy on issues relating to biopharmaceuticals for rare diseases driven by genetic causes generally, or BioMarin Pharmaceutical specifically.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
ALKERMES, INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to the biopharmaceutical industry generally, and Alkermes, Inc. specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
HEARTLAND FOOD PRODUCTS GROUP via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to U.S. based sweetener production
Provide strategic counsel and advocate on issues related to U.S. based sweetener production
Filing targets: Agriculture, Dept of (USDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, U.S. Trade Representative (USTR), White House Office
NOVARTIS via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies, EPIC Act; Most Favored Nation (MFN) policy, drug pricing policies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FRESENIUS MEDICAL CARE NORTH AMERICA (FKA FRESENIUS MEDICAL CARE) via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Medicare reimbursement; End stage renal disease (ESRD) payment reforms; extension of Medicare sequester; telehealth policy and waivers; issues pertaining to Medicare Secondary Payer Act; oral-only ESRD drugs
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE PROCTER & GAMBLE COMPANY via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to OTC drug regulation, FDA, FTC, and healthcare policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
ASSOCIATION FOR RESPONSIBLE HEALTHCARE INVESTMENT via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocacy on federal policy proposals impacting private investment in healthcare. This includes legislative and regulatory initiatives related to clinical autonomy, workforce support, access to care in underserved communities, health system modernization, and transparency and accountability in healthcare delivery and investment.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGENERON PHARMACEUTICALS, INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to matters of importance to domestic pharmaceutical manufacturers
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SARGENTO FOODS INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to H.R.1394/S.184 - Codifying Useful Regulatory Definitions (CURD) Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PFIZER, INC via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the pharmaceutical industry generally and/or Pfizer specifically.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to higher education and research appropriations
Provide strategic counsel and advocate on issues related to higher education and research appropriations
Filing targets: SENATE
AMGEN INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide advice and strategic counsel with regard to matters that could impact biopharmaceutical manufacturers generally and Amgen specifically, including Medicare Part D, Medicare Part B, Health Care Reform, Medicaid, FDA regulatory issues, and corporate tax reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Advise and advocate on clients behalf regarding ongoing public policy concerns impacting the innovative biopharmaceutical industry in Congress and throughout the Administration.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GLAXOSMITHKLINE, INC via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Strategic guidance and advocacy on health care related issues to include: healthcare reform, HIV/AIDS, bio-defense, Medicare/Medicaid and FDA
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHI HEALTH, LLC, D/B/A PHI AIR MEDICAL via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to ambulance legislative and regulatory issues.
Provide strategic counsel and advocate on issues related to ambulance legislative and regulatory issues.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE
ORCA BIO via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to regulatory and reimbursement policies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WK KELLOGG CO (FKA KELLOGG COMPANY) via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocacy on issues related to federal nutrition assistance programs
Filing targets: Agriculture, Dept of (USDA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
NUVATION BIO INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to FDA policy and treatment of Non-Small Cell Lung Cancer
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
UNILEVER via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to food labeling, nutrition standards, tax, tariffs and other matters of importance to Unilever
Provide strategic counsel and advocate on issues related to food labeling, nutrition standards, tax, tariffs and other matters of importance to Unilever
Provide strategic counsel and advocate on issues related to food labeling, nutrition standards, tax, tariffs and other matters of importance to Unilever
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STAMFORD HEALTH via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and policy analysis related to federal payment and policy issues and government funding impacting hospitals generally and Stamford Health specifically
THE CHILDREN'S HOSPITAL OF PHILADELPHIA via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and policy analysis related to federal payment and policy issues and government funding impacting hospitals generally and The Children's Hospital of Philadelphia specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE REGENTS OF THE UNIVERSITY OF MICHIGAN via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to higher education and appropriations
Filing targets: Education, Dept of, HOUSE OF REPRESENTATIVES, SENATE
FEDERATION OF AMERICAN HOSPITALS via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to health policy and hospitals
Provide strategic counsel and advocate on issues related to health policy and hospitals
Filing targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
ALLIANCE FOR REGENERATIVE MEDICINE via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic guidance and advocacy on issues related to regulation of, access to, and reimbursement for regenerative medicine products, and any other issues related to the Alliance for Regenerative Medicine specifically.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
REAL TIME MEDICAL SYSTEMS via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel related to federal health care policy impacting nursing facilities and assisted living settings.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
FAIRMOUNT FUNDS MANAGEMENT LLC via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to FDA's regulatory framework for drug-drug combination products and other matters of importance
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FINDHELP via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocacy on federal health policy related to social care programs.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, Veterans Affairs, Dept of (VA), White House Office
SARGENTO FOODS INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · RR
Provide strategic counsel and advocate on issues related to H.R.1394/S.184 - Codifying Useful Regulatory Definitions (CURD) Act.
UNILEVER via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to food labeling, nutrition standards, tax, tariffs and other matters of importance to Unilever
Provide strategic counsel and advocate on issues related to food labeling, nutrition standards, tax, tariffs and other matters of importance to Unilever
Provide strategic counsel and advocate on issues related to food labeling, nutrition standards, tax, tariffs and other matters of importance to Unilever
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STAMFORD HEALTH via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and policy analysis related to federal payment and policy issues and government funding impacting hospitals generally and Stamford Health specifically
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE CHILDREN'S HOSPITAL OF PHILADELPHIA via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and policy analysis related to federal payment and policy issues and government funding impacting hospitals generally and The Children's Hospital of Philadelphia specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE REGENTS OF THE UNIVERSITY OF MICHIGAN via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to higher education and appropriations
Filing targets: Education, Dept of, HOUSE OF REPRESENTATIVES, SENATE
WK KELLOGG CO (FKA KELLOGG COMPANY) via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocacy on issues related to federal nutrition assistance programs
Filing targets: Agriculture, Dept of (USDA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
ALLIANCE FOR REGENERATIVE MEDICINE via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic guidance and advocacy on issues related to regulation of, access to, and reimbursement for regenerative medicine products, and any other issues related to the Alliance for Regenerative Medicine specifically.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
REAL TIME MEDICAL SYSTEMS via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel related to federal health care policy impacting nursing facilities and assisted living settings.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
FINDHELP via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocacy on federal health policy related to social care programs.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, Veterans Affairs, Dept of (VA), White House Office
STRYKER CORPORATION via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide guidance and advocacy with regard to regulations and legislation that could impact the medical device industry generally, and Stryker Corporation specifically.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
RECESS via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and guidance regarding regulatory policy issues pertaining to CBD in food and beverage.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and policy analysis related to federal payment and policy issues and government funding impacting hospitals and health plans generally and Mass General Brigham specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE
PTC THERAPEUTICS via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide guidance and advocacy with regard to regulations and legislation that could impact the pharmaceutical industry generally, and PTC specifically.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BAYER CORPORATION via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide lobbying support on key issues and providing intelligence and policy tracking for relevant federal policy developments that could impact the pharmaceutical and medical device industry generally, and Bayer specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
AMERICAN SOCIETY OF GENE AND CELL THERAPY via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Strategic advice and counsel on issues impacting gene and cell therapy development and access
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
WALGREEN CO. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide policy analysis, strategic advice and direct advocacy support to Walgreens related to public policy priorities for the retail pharmacy industry
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ORCA BIO via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to regulatory and reimbursement policies.
EDWARDS LIFESCIENCES LLC via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide analysis and strategic advocacy support services to Edwards Lifesciences public policy priorities, including FDA regulatory and CMS coverage and reimbursement issue
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Advise and advocate on client's behalf regarding ongoing public policy concerns impacting the innovative biotechnology industry in Congress and throughout the Administration
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
CARDINAL HEALTH via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to health, tax and trade policy
Provide strategic counsel and advocate on issues related to health, tax and trade policy
Provide strategic counsel and advocate on issues related to health, tax and trade policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
NUVATION BIO INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to FDA policy and treatment of Non-Small Cell Lung Cancer
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
GRADY HEALTH SYSTEM via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and policy advocacy related to federal payment and policy issues and government funding impacting hospitals generally and Grady Health System specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
VAXCYTE, INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to vaccine development
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NEUROCRINE BIOSCIENCES, INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biopharmaceutical industry generally such as drug pricing and telehealth policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Providing advice, counsel, and services to support the Pharma & Biopharma Outsourcing Association's public policy priorities
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
FEDERATION OF AMERICAN HOSPITALS via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to health policy and hospitals
Provide strategic counsel and advocate on issues related to health policy and hospitals
Filing targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
NYU LANGONE HEALTH via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and policy analysis related to federal payment and policy issues and government funding impacting hospitals generally and NYU Langone Health specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide guidance and strategic advice regarding regulation and coverage of medical devices, including diagnostic tests
Filing targets: Bureau of Industry and Security (BIS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Intl Trade Administration (ITA), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
FAIRMOUNT FUNDS MANAGEMENT LLC via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to FDA's regulatory framework for drug-drug combination products and other matters of importance
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACADEMY OF NUTRITION AND DIETETICS via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to health care coverage for Medical Nutritional Therapy and Intensive behavior health and other priorities for the Academy of Nutrition and Dietetics
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PROLACTA BIOSCIENCE, INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to regulation of, access to, and reimbursement for human-milk based exempt formulas
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
A PLACE FOR MOM, INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic guidance and advocacy regarding the Senior Living Referral sector.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALKERMES, INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to the biopharmaceutical industry generally, and Alkermes, Inc. specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
BREAKTHROUGH T1D (F/K/A JDRF) via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to Type 1 Diabetes policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ADVOCATE HEALTH via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on health care policy, including matters impacting the hospital industry and federal appropriations
Provide strategic counsel and advocate on health care policy, including matters impacting the hospital industry and federal appropriations
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
HEARTLAND FOOD PRODUCTS GROUP via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to U.S. based sweetener production
Provide strategic counsel and advocate on issues related to U.S. based sweetener production
Filing targets: Agriculture, Dept of (USDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, U.S. Trade Representative (USTR), White House Office
THE PROCTER & GAMBLE COMPANY via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to OTC drug regulation, FDA, FTC, and healthcare policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
ASSOCIATION FOR RESPONSIBLE HEALTHCARE INVESTMENT via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocacy on federal policy proposals impacting private investment in healthcare. This includes legislative and regulatory initiatives related to clinical autonomy, workforce support, access to care in underserved communities, health system modernization, and transparency and accountability in healthcare delivery and investment.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGENERON PHARMACEUTICALS, INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to matters of importance to domestic pharmaceutical manufacturers
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to higher education and research appropriations
Provide strategic counsel and advocate on issues related to higher education and research appropriations
Filing targets: Defense, Dept of (DOD), Education, Dept of, HOUSE OF REPRESENTATIVES, SENATE, White House Office
BIOMARIN PHARMACEUTICAL INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocacy on issues relating to biopharmaceuticals for rare diseases driven by genetic causes generally, or BioMarin Pharmaceutical specifically.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
PFIZER, INC via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the pharmaceutical industry generally and/or Pfizer specifically.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMGEN INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide advice and strategic counsel with regard to matters that could impact biopharmaceutical manufacturers generally and Amgen specifically, including Medicare Part D, Medicare Part B, Health Care Reform, Medicaid, FDA regulatory issues, and corporate tax reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Advise and advocate on clients behalf regarding ongoing public policy concerns impacting the innovative biopharmaceutical industry in Congress and throughout the Administration.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GLAXOSMITHKLINE, INC via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Strategic guidance and advocacy on health care related issues to include: healthcare reform, HIV/AIDS, bio-defense, Medicare/Medicaid and FDA
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies, EPIC Act; Most Favored Nation (MFN) policy, drug pricing policies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORCA BIO via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · RR
Provide strategic counsel and advocate on issues related to regulatory and reimbursement policies.
RECESS via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide strategic counsel and guidance regarding regulatory policy issues pertaining to CBD in food and beverage.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
STRYKER CORPORATION via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide guidance and advocacy with regard to regulations and legislation that could impact the medical device industry generally, and Stryker Corporation specifically.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide strategic counsel and policy analysis related to federal payment and policy issues and government funding impacting hospitals and health plans generally and Mass General Brigham specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PTC THERAPEUTICS via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide guidance and advocacy with regard to regulations and legislation that could impact the pharmaceutical industry generally, and PTC specifically.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FINDHELP via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide strategic counsel and advocacy on federal health policy related to social care programs.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, Veterans Affairs, Dept of (VA), White House Office